Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases.
A new dosage form consisting of small activated carbon particles which adsorb Aclacinomycin A, Adriamycin, Mitomycin C or Pepleomycin was prepared in order to deliver larger amounts of anticancer agents to the lymph nodes through the high ability of lymphatics to adsorb particles. Animal experiments showed that: The LD50 values of the new dosage form were higher than those of the dosage in solution. The concentration of agents in lymph nodes was maintained at a higher level in the new dosage form than in solution form. Clinically 33% of lymphnodal metastatic lesions became degenerative or inflammatory after a single administration.
D015250:Aclarubicin; D000327:Adsorption; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000627:therapeutic use; D002606:Charcoal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007928:Lethal Dose 50; D008207:Lymphatic Metastasis / Q000188:drug therapy*; D008297:Male; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage / Q000627:therapeutic use; D009279:Naphthacenes / Q000008:administration & dosage / Q000627:therapeutic use; D017663:Peplomycin
D000970:Antineoplastic Agents; D008937:Mitomycins; D009279:Naphthacenes; D001761:Bleomycin; D002606:Charcoal; D016685:Mitomycin; D017663:Peplomycin; D015250:Aclarubicin; D004317:Doxorubicin